INFO & CONTACTS:  +39 02 2390 1

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Phase: Phase I-II clinical trials

Principal Investigator: Dott. Pietrantonio Filippo

Main Facility: Oncologia Medica Gastroenterologica

Drug: MK-2870 (SKB264; sacituzumab tirumotecan; sac-TMT)

Pathologies: Bile duct cancer

ClinicalTrials.gov: Read the details about clinical trials

This is a Phase 1/2, nonrandomized, multisite, open-label study of MK-2870 monotherapy or in combination with other anticancer agents in GI cancers. Approximately 180 eligible participants will be nonrandomly allocated to one of the following disease cohorts: 

• Cohort 3: 2L+ BTC (approximately 80 participants [approximately 40 participants each at 4 mg/kg and 5 mg/kg MK-2870]) 

• Cohort 4: 1L BTC (approximately 50 participants, including dose escalation) 

The primary objectives of the study are to evaluate DLTs (Cohort 4, DoseEscalation Phase only), AEs, and discontinuation of study intervention due to AEs, and to evaluate ORR per RECIST 1.1 as assessed by BICR. 

For Cohort 4, the totality of data, including safety and tolerability will be evaluated to determine the preliminary RP2D for MK-2870 in combination with cisplatin and pembrolizumab in Cohort 4 before opening enrollment in the Efficacy Phase of either cohort.

Last update: 16/07/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe